We studied the changes in pulmonary hemodynamics and lung wet weight induced with opsonized zymosan (OZ) 
Recirculation of the perfusate was begun after the pulmonary venous effluent was clear of blood. The final circulating volume was 300 ml. The lungs were inflated to 20 cm H20 several times during the experiment to prevent atelectasis and were continuously inflated with airway pressure of 1 cm H20 with a 95% 02-5% CO2 gas mixture. Left atrial pressure was set at 3 cm H20.
Mean pulmonary artery pressure (Ppa) and left atrial pressure (PFa) were monitored continuously by pressure transducers (Gould Pd23ID and P50, respectively). Pulmonary capillary pressure (Pcap) was determined using the double occlusion method. 13 The arterial and venous resistances were determined by partitioning the upstream and downstream resistances.
The capillary filtration coefficient (Kf,C) was measured during an isogravimetric period with a method we have described. 14 
Experimental Protocols
PMNs (2.5 x 10' to 3.5 x 10' cells/ml) were suspended in 1 ml buffered Ringer-albumin solution (0.5 g%). After a 10-minute baseline equilibration period, the cells were injected slowly into the pulmonary artery catheter over 5 minutes. After another 10-minute equilibration period, 5 mg OZ was added to the perfusate reservoir. Pulmonary hemodynamic and lung weight changes were measured for the next 45 minutes. Control experiments were made using either PMN or OZ alone. The effect of increased Pcap in mediating the increases in lung weight was examined using the vasodilator papaverine (90 ,M) (Sigma)15 added to the perfusate reservoir 10 minutes before addition of PMNs and OZ.
We examined the contribution of superoxide anion (O2) generation to pulmonary edema formation by adding superoxide dismutase (Pharmacia Corporation, Basel, Switzerland) to the perfusate reservoir 10 minutes before infusion of PMNs (final superoxide dismutase concentration, 300 units/ml). The role of hydrogen peroxide (H202) was studied using catalase (Sigma) added to the perfusate reservoir 10 minutes before infusion of PMNs (final catalase concentration, 300 units/ml). The role of the hydroxyl radical (OH.) was studied by adding superoxide dismutase and catalase simultaneously to the perfusate reservoir 10 minutes before infusion of PMNs, each at a final concentration of 300 units/ml. We examined the effects of a monoclonal antibody (MAb), IB4 (an IgG2A), directed against CD18, the common (3-subunit of structurally related adhesion receptors on leukocytes, LFA-1, Mac-1, and P150,9510 on the pulmonary edema induced by OZstimulated PMNs. We also studied the effects of a control MAb that does not prevent PMN adhesion:
OKM-1 (an IgGl), directed against CDi1b (the asubunit of Mac-1).10 The MAbs were circulated in the perfusate for 10 minutes before the infusion of PMNs into the pulmonary circuit. The mouse ascites fluids containing the MAbs were diluted to yield a final antibody concentration of 3.3 ,g/ml or 40 gg/106 PMNs. Both MAbs contained less than 300 pg/ml endotoxin.
Transendothelial 125I-Albumin Permeability Polycarbonate micropore membranes (13-mm diameter, 0.8-,um pore size) (Nucleopore Corp., Pleasanton, Calif.) were coated with gelatin and fibronectin, and the permeability assay system was assembled as described.'6 Bovine pulmonary artery endothelial cells (CCL-209) of Del Vecchio and Smith17 were obtained at 16 serial passages from the American Type Tissue Collection, Rockville, Md. Endothelial cells (4x i05) suspended in 0.5 ml culture medium were placed onto each membrane and allowed to grow to confluence. The endothelial cells were characterized as having factor VIII antigen, angiotensin converting enzyme activity, and typical cobblestone morphology.18 The system consisted of two fluid-filled compartments connected via the Nucleopore membrane with one side covered by the endothelial cell monolayer. The upper compartment contained a total volume of 700 ,ul Dulbecco's modified Eagle medium (DMEM) (GIBCO Laboratories, Wheaton, Ill.) with 0.5% bovine serum albumin. The upper compartment was held within Styrofoam flotation rings and floated in 25 ml DMEM with 0.5% albumin contained in the lower compartment. The lower compartment was stirred constantly to ensure complete mixing, and the entire system was maintained at 370 C in a water bath. Control wells were run for each experiment, containing DMEM and`PI-albumin in the upper well. Each monolayer system served as its own control. We have described previously the method for quantifying endothelial permeability.19
The transendothelial 125I-albumin permeability studies were made using human PMNs and bovine pulmonary arterial endothelial cells. Human PMNs were layered onto endothelial cells 30 minutes before challenge with OZ (5 mg/ml). The ratio of PMNs and endothelial cells in each well was 1: 1, 5: 1, and 10: 1.
PI-albumin was added to the luminal well, and tracer flux was examined. The`PI-albumin permeability was measured for 60 minutes after PMNs were added to the monolayer. We also examined the effects of IB4 on the OZ-induced endothelial monolayer permeability alterations. PMNs were pretreated with IB4 (10 ,g/ml) or with OKM-1 (10 ,ug/ml) for 5 minutes at 370 C before the cells were added to the endothelial monolayer. Neutrophil Activation Assays Adherence of human PMNs to human umbilical vein endothelial cell (HUVEC) monolayers20 was tested as described.2' 51Cr-labeled PMNs (2x106 cells/ml DMEM) were distributed at 1 ml per well over the confluent HUVEC monolayer. The cells were incubated (370 C, 5% C02, 98% humidity) for different times in DMEM without serum. At the end of the incubation period, the endothelial monolayers were gently washed three times with phosphate buffered saline (Ca2' and Mg2+ free; pH 7.4) to remove the nonadherent PMNs. The endothelial monolayers were kept overnight under 1 ml of 1N NaOH at 40 C.
The cell lysates were scraped, collected in polypropylene test tubes, and counted for radioactivity in a gamma counter (Tm Analytical, Inc., Brandon, Fla.). Either phorbol myristate acetate (20 ng/ml) or OZ (5 mg/ml) was used to stimulate PMNs. The effects of IB4 (10 ,ug/ml) and OKM-1 (10 ,ug/ml) on the adherence responses were examined.
In other studies, PMNs were treated with IB4 (10 ,ug/ml) to determine the effect of CD18 on PMN activation responses after OZ phagocytosis. Production of 02-was determined by the reduction of ferricytochrome C (type III, horse heart, Sigma).22 OZ (5 mg/ml) was used to stimulate PMNs. Elastase and myeloperoxidase release by OZ-stimulated PMNs also were determined as described.23,24 Quantification of Neutrophil Distribution and Phagocytosis PMN distribution on cultured endothelial cell monolayers and phagocytosis of OZ were quantified using 1-,um-thick plastic histological sections. The morphological assessment was made in parallel with transendothelial 1251-albumin flux experiments described above. The three experimental groups consisted of endothelial monolayers containing PMNs with OZ challenge and either IB4 or OKM-1 pretreated PMNs with OZ challenge. The ratio of PMNs and endothelial cells was 5: 1 for each of the three experimental groups.
At the termination of the experiment, monolayers were fixed in 2.5% glutaraldehyde in 0.05 M cacodylate buffer, dehydrated in a graded series of ethanol, and embedded in glycol methacrylate. Sections ily on the venous side of the pulmonary circuit ( Table  1 ). The vasodilator, papaverine, inhibited the pulmonary hypertension and weight gain (Figure 1, right  panel) , indicating that the lung weight gain was the consequence of the rise in Pca.
To determine which products of PMNs mediated the response, superoxide dismutase, catalase, and both enzymes together were added to the perfusate. There was no reduction in the pulmonary vasoconstriction, hypertension, and lung weight gain after addition of the antioxidant enzymes ( Figure 2) . Superoxide dismutase or catalase infusion in control experiments had no independent effect on pulmonary hemodynamics and lung weight gain.
Pretreatment of the PMNs with the monoclonal antibody IB4, directed against the PMN adhesion epitope on the p-chain of CD18,10 inhibited the increase in lung weight gain induced by addition of OZ ( Figure 3 ). IB4 also inhibited the initial phase of the pulmonary hypertension response (Figure 3) . In contrast, the control antibody OKM-1, directed against an irrelevant epitope on the a-subunit of Mac-i (CDiib),l1 did not affect the hypertension or the increase in lung wet weight induced by OZ.
In Vitro Studies
The MAb IB4 inhibited adherence of PMNs to the human umbilical vein endothelial monolayer, whereas the antibody OKM-1 had no significant effect ( Table 2 ). The inhibition of adherence by IB4 was similar in PMNs stimulated with phorbol myristate acetate (20 ng/ml) or with OZ (5 mg/ml) ( Table 2 ). OZ (5 mg/ml) resulted in generation of 02 by human PMNs (Table 3) , which was not significantly altered by pretreatment of PMNs with IB4 (Table 3) . IB4 also did not prevent the release of proteases by PMNs after OZ challenge (Table 4) .
PMNs increased endothelial monolayer permeability to`PI-albumin after challenging PMNs with OZ ( Figure 4 ). This effect was dependent on the numbers of PMNs layered onto the endothelial monolayer increasing from a PMN to endothelial cell ratio of 1: 1 to 10: 1 ( Figure 4, upper panel) . The increased permeability to`PI-albumin with OZ was inhibited by pretreating the PMNs with IB4, whereas OKM-1 was ineffective (Figure 4, lower panel) . Mor 1.94+1.56, and of these, only 0.25+0.14 PMN per field was adherent to the endothelial cell membrane. The percentage of PMNs containing OZ particles for both control and IB4 -treated groups was greater than 70% and not significantly different from each other (Table 5 ). In contrast to IB4, OKM-1 did not prevent PMN adherence to the endothelium. Moreover, OZ particles also were present in the OKM-1-treated PMNs as in the control PMNs and IB4-treated PMNs challenged with OZ (Table 5 ).
Discussion
The results of the present study indicate that OZ challenge of lungs perfused with PMNs caused pulmonary vasoconstriction and increases in pulmonary capillary hydrostatic pressure, vascular permeability, and lung weight. The increase in lung weight by 50% over the control wet lung weight during the 45-minute study period may, in part, be the result of increase in pulmonary vascular volume caused by distension of the vascular bed. However, a substantial portion of the increase in lung weight can be attributed to pulmonary edema, because the increase was associated with increases in both pulmonary capillary hydrostatic pressure and vascular permeability. The increase in lung wet weight also occurred steadily over the 45-minute study period, in contrast to the rapid and sustained weight gain that occurs with pulmonary vascular distension,25 suggesting that the progressive component of the weight increase was due to the development of pulmonary edema.
The pulmonary vasoconstriction occurred primarily in the postcapillary vessels. The resultant rise in pulmonary capillary hydrostatic pressure was essential to the development of pulmonary edema, because papaverine, a pulmonary vasodilator,15 prevented the increase in capillary pressure, as well as the increase in lung weight induced with OZ.
Superoxide dismutase, catalase, or catalase plus superoxide dismutase did not prevent the increases in pulmonary vascular resistance and lung weight, suggesting that these alterations induced by OZ challenge of PMNs are independent of oxidant generation. By exclusion, these results point to the role Stimulation of PMNs layered on the endothelial monolayer with OZ resulted in increases in endothelial monolayer permeability, which is consistent with the increase in the Kf,C observed after OZ challenge of the PMN-perfused lungs. A similar effect of PMNs challenged with OZ has been noted in airway epithelial monolayers in culture. 26 The increase in endothelial permeability was associated with phagocytosis of the zymosan particles and required an optimal ratio of PMNs-to-target cells (i.e., the response was observed at a ratio of 5:1, but not at 1:1). This finding indicates that PMN secretory products need to attain high concentrations to induce endothelial injury. The ratio of effector-to-target cells of 10: 1 did not further increase the response. One explanation for this lack of effect is that a very high number of PMNs may form an additional barrier to the transport of`PI-albumin, thereby masking the increase in endothelial permeability.
The pulmonary vasoconstriction and the lung weight gain may be critically dependent on PMN adhesion to endothelial cells. PMN treatment with MAb IB4 blocked PMN adhesion to the endothelium (Table 2 ) and also inhibited the lung weight gain and the early pulmonary vasoconstriction after OZ challenge ( Figure 3) . In intact lungs, IB4 may prevent adhesion to the pulmonary vascular endothelial cells as well as intravascular PMN aggregation, but this study does not allow us to distinguish between these two possibilities. However, the endothelial monolayer studies showed that inhibition of PMN adherence induced with anti-CD18 MAb prevented the increase in permeability of endothelial monolayers (Figure 4, lower panel) , suggesting the critical role of adhesion in the response. The effects of IB4 were specific in that the control MAb OKM-1, which did not inhibit adhesion to the endothelium (Table 2) , also did not affect either lung weight gain or endothelial monolayer permeability in response to OZ challenge. 
